Profile
International Journal of Nursing & Clinical Practices Volume 7 (2020), Article ID 7:IJNCP-320, 3 pages
https://doi.org/10.15344/2394-4978/2020/320
Short Communication
Suggestions for Protecting Breast Cancer Patients Receiving Outpatient Chemotherapy and Their Families Against the Exposure Risk from Salivary Cyclophosphamide

Tomoe Makino1, Noboru Hasegawa1*, Rie Takizawa1, Chie Matsumoto1, Takanori Wagatsuma2, Keiko Yabushita2, Hiroko Kubo3 and Kenjiro Aogi4

1Ishikawa Prefectural Nursing University, 1-1 Gakuendai, Kahoku, Ishikawa 929-1210, Japan
2Kanazawa Medical University Hospital, 1-1 Daigaku, Ucninada, Ishikawa, 920-0265, Japan
3University of Fukui Hospital, 23-3, Matsuokashimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui, 910-1193, Japan
4Independent Administrative Agency National Hospital Organization Shikoku Cancer Center, 160, Kou, Minamiumemoto-machi, Matsuyama, Ehime, 791-0280, Japan
Prof. Noboru Hasegawa, Department of Health and Medical Sciences, Ishikawa Prefectural Nursing University, 1-1 Gakuendai, Kahoku, Ishikawa 929-1210, Japan; E-mail: hsgwn@ishikawa-nu.ac.jp
05 February 2020; 15 February 2020; 17 February 2020
Makino T, Hasegawa N, Takizawa R, Matsumoto C, Wagatsuma T , et al. (2020) Suggestions for Protecting Breast Cancer Patients Receiving Outpatient Chemotherapy and Their Families Against the Exposure Risk from Salivary Cyclophosphamide. Int J Nurs Clin Pract 7: 320. doi: https://doi.org/10.15344/2394-4978/2020/320
This work was supported by JSPS KAKENHI Grant Number JP16K12069.

References

  1. Kelsey JL (1993) Breast cancer epidemiology: summary and future directions. Epidemiol Rev 15: 256-263. [CrossRef] [Google Scholar] [PubMed]
  2. Connor TH, McDiarmid MA (2006) Preventing occupational exposures to antineoplastic drugs in health care settings. CA Cancer J Clin 56: 354-365. [CrossRef] [Google Scholar] [PubMed]
  3. Kromhout H, Hoek F, Uitterhoeve R, Huijbers R, Overmars RF, et al. (2000) Postulating a dermal pathway for exposure to antineoplastic drugs among hospital workers. Applying a conceptual model to the results of three workplace surveys. Ann OccupHyg 44: 551-560. [CrossRef] [Google Scholar] [PubMed]
  4. Meijster T, Fransman W, Veldhof R, Kromhout H (2006) Exposure to antineoplastic drugs outside the hospital environment. Ann Occup Hyg 50: 657-664. [CrossRef] [Google Scholar] [PubMed]
  5. Valero-Garcia S, Poveda-Andes JL (2018) Hazardous drugs levels in compounding area surfaces of Hospital Pharmacies Services: multicentric study. Farm Hosp 42: 152-158. [CrossRef] [Google Scholar] [PubMed]
  6. National Institute for Occupational Safety and Health (2004) Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings. Ohio: NIOSH-Publications Dissemination, USA.
  7. Kanda K, Hirai K, Iino K, Nomura H, Yasui H, et al. (2017) Salient features and outline of the Joint Japanese Guidelines for Safe Handling of Cancer Chemotherapy Drugs. Asia Pac J Oncol 4: 304-312. [CrossRef] [Google Scholar] [PubMed]
  8. Juma FD, Rogers HJ, Trounce JR (1979) The kinetics of salivary elimination of cyclophosphamide in man. Br J Clin Pharmacol 8: 455-458. [CrossRef] [Google Scholar] [PubMed]
  9. Powis G, Reece P, Ahmann DL, Ingle JN (1987) Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients. Cancer Chemother Pharmacol 20: 219-222. [CrossRef] [Google Scholar] [PubMed]
  10. Yuki M, Sekine S, Takase K, Ishida T, Sessink PJ, et al. (2013) Exposure of family members to antineoplastic drugs via excreta of treated cancer patients. J Oncol Pharm Pract 19: 208-217. [CrossRef] [Google Scholar] [PubMed]
  11. Haubitz M (2007) Acute and long-term toxicity of cyclophosphamide. Transplantationsmedizin 19: 26-31. [Google Scholar]